Prescient Therapeutics nears a pivotal moment as PTX-100 Phase 2a trial hits key milestone
As cancer rates around the world climb for a range of reasons, one of the...
As cancer rates around the world climb for a range of reasons, one of the...
While part of the story is an increased ability to diagnose cancers early, thanks to...
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.